Proguanil
Malaria,Falciparum
Duke UniversitySmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Malaria,Falciparum cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FANSIDAR COMPONENT SULFADOXINE Duke University | Phase 4 | BB |
Alhydrogel Malaria Vaccine National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | CC |
P. FALCIPARUM NF54 SPOROZOITE Sanaria Inc. | Phase 1 | CC |
ama1-c1 National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | CC |
Same molecule, other indications
Proguanil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →